Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
AssigneeCIS Biotech, Inc.
InventorSvetlana A. Dambinova
Life of this patent
Estimating the term…
Abstract
A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
Claims13
A method for aiding in the diagnosis that a human is having transient ischemic attacks (TIA), pre-stroke, acute stroke, or traumatic brain injury (TBI) comprising:
- a) obtaining a test sample of human blood, serum, or plasma from a human subject at the time the human subject is suspected of having transient ischemic attacks (TIA), pre-stroke, acute stroke, or traumatic brain injury (TBI);
- b) analyzing the obtained test sample for the amount of NR2A N-terminal domain fragment peptide having SEQ ID NO:3 and NR2B N-terminal domain fragment peptide having SEQ ID NO:12 (NR2A-B receptor peptides);
- c) comparing the result of step (b) with a corresponding reference amount of said NR2A-B receptor peptides, wherein the corresponding reference amount is derived from a population of apparently healthy human subjects;
- and
- d) if the amount determined in step (b) exceeds the corresponding reference amount, diagnosing said human as having an increased probability of having transient ischemic attacks (TIA), pre-stroke, acute stroke, or traumatic brain injury (TBI).
Dependencies are inferred from the claim text.